• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Forest Laboratories, moksha8 form strategic alliance for Latin America

Forest Laboratories, moksha8 form strategic alliance for Latin America

October 24, 2012
CenterWatch Staff

Forest Laboratories, an international pharmaceutical company, and moksha8, a pharmaceutical company that commercializes CNS medicines in Latin America, have entered into a broad strategic alliance that will provide Forest with a commercial footprint in Latin America and give moksha8 access to Viibryd and potentially other Forest products for the Latin American market.

The alliance includes an exclusive license from Forest to moksha8 to commercialize Viibryd, a novel antidepressant for the treatment of major depressive disorder (MDD). In addition, Forest will provide up to $125 million in financing to moksha8 in several tranches over a two-year period, conditioned upon moksha8 achieving certain business goals. At the conclusion of this two-year period, Forest will have the option to acquire moksha8 in a merger transaction. The moksha8 shareholders will also have a put option at such time, provided that moksha8 has achieved certain business objectives.

"We are pleased to enter into this transaction with moksha8, which provides Forest access in a risk controlled manner to a high quality commercial operation in Latin America, one of the largest and fastest growing pharmaceutical markets in the world,” said David Solomon, senior vice president, corporate development and strategic planning, Forest Laboratories. “Moksha8 is uniquely positioned to commercialize novel products such as Viibryd in Latin America, and Forest will augment the moksha8 pipeline through our broad global partner network and business development reach. This alliance will in time contribute important incremental profits and growth to Forest and is consistent with Forest's strategy to improve returns on our product investments through fiscally responsible international expansion."

In connection with the alliance, moksha8 has expanded its license arrangement with Watson Pharmaceuticals to extend moksha8's rights to commercialize a portfolio of Watson CNS branded generic products in Brazil and Mexico and has bought out Watson's minority equity position in moksha8. Other financial terms were not disclosed.

“We are also pleased with the agreement between moksha8 and Watson, as Watson's high quality branded generic products are complementary to Viibryd and the other novel brands Forest expects to provide to moksha8," said Soloman.

Today, the Latin America pharmaceutical market is $67 billion with a CAGR of over 14% over the last 5 years. Brazil and Mexico account for two thirds of the Latin America market value. The CNS market in Latin America is estimated to be approximately $6 billion.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing